Summary Two polymorphisms of the aromatase and estrogen receptor genes appeared to interact to influence the risk of hip fractures in women. Introduction Allelic variants of the aromatase gene have been associated with bone mineral density and vertebral fractures. Our objective was to analyze the relationship between two polymorphisms of the aromatase and estrogen receptor genes and hip fractures. Methods We studied 498 women with hip fractures and 356 controls. A C/G polymorphism of the aromatase gene and a T/C polymorphism of the estrogen receptor α gene were analyzed using Taqman assays. Aromatase gene expression was determined in 43 femoral neck samples by real-time RT-PCR. Results There were no significant differences in the overall distribution of genotypes between the fracture and control groups. However, among women with a TT genotype of the estrogen receptor, the CC aromatase genotype was more frequent in women with fractures than in controls (39 vs. 23%, p=0.009). Thus, women homozygous for T alleles of estrogen receptor and C alleles of aromatase were at increased risk of fracture (odds ratio 2.0; 95% confidence interval 1.2-3.4). The aromatase polymorphism was associated with RNA levels in bone tissue, which were three times lower in samples with a CC genotype (p=0.009). Conclusions These common polymorphisms of the aromatase and estrogen receptor genes appear to interact, influencing the risk of hip fractures in women.
Introduction
Genetic factors are known to have an important influence on bone mass and the risk of developing osteoporosis [1] [2] [3] . Given the role of estrogen in bone homeostasis, genes related to estrogen metabolism are likely candidates to contribute to such hereditary influence. There are two types of estrogen receptors, α and β, encoded by genes situated in chromosomes 6 and 14 respectively. Type α receptors are usually considered the most important in mediating the effects of estrogen effects on bone [4, 5] . The main source of estrogen in postmenopausal women is the aromatization of androgenic precursors, a reaction catalyzed by aromatase, the product of the CYP19A1 gene [6] . In humans the gene is expressed not only in the gonads, but also in other tissues, including the adipose tissue and bone. The influence of aromatase-derived estrogen on the skeleton is revealed by the reduction of bone mineral density (BMD) in postmenopausal women treated with aromatase inhibitors [7] .
The CYP19A1 gene is located on chromosome 15q21 and spans about 120 kb. It has a 30-kb coding region and a long 5′ region, spanning about 90 kb. This 5′ region contains regulatory sequences and several variants of the first exon, whose transcription is driven by different tissuespecific promoters. Several investigators have reported an association between some common polymorphisms of the aromatase gene and BMD [8] [9] [10] . We have previously shown that a gene-gene interaction between aromatase and estrogen receptor α appears to influence BMD in postmenopausal women [11] . Since hip fractures are the most devastating consequence of osteoporosis, the objective of this study was to determine the possible relationship between those polymorphisms in the aromatase and estrogen receptor genes and hip fractures.
Materials and methods

Study participants
We studied 854 postmenopausal women, 498 with hip fractures and 356 controls. Consecutive women admitted to hospital because of a hip fracture were included, unless they fitted the exclusion criteria. We excluded women with fractures due to high-impact trauma (such as traffic accidents and falls from a height), diseases causing secondary osteoporosis (cancer, rheumatoid arthritis, malabsorption, severe systemic diseases, etc.) or taking drugs known to have a deleterious effect on bone metabolism (corticosteroids, anticonvulsants). Control women aged over 60, without known fractures after the menopause and not receiving anti-osteoporotic therapy were recruited by oral and written announcements from various sources to prevent a preferential selection bias (hospital workers, civic associations, religious groups, and geriatric residences). All participants were interviewed by one of the investigators to check the absence of exclusion criteria. Subjects with non-Spanish ancestry were excluded. Calcium intake from dairy products was estimated by a questionnaire [12] . Recreational physical activity was graded semiquantitatively, and women were considered to exercise if they walked more than 3 km daily or were engaged in other sport activities. Alcohol intake was defined as a daily intake of more than 10 g. Women were regarded as smokers if they had a present or past history of smoking at least 5 cigarettes per day for a minimum of 5 years. Age at menopause was established by recalling the last menstruation. The study protocol was approved by the Institutional Committee of Ethics in Clinical Research, and informed consent was obtained from study participants or their representatives.
Genotyping
DNA was isolated from the peripheral blood or from buccal swabs with a commercial kit (Qiagen, Hilden, Germany), following the manufacturer's instructions. A C/G SNP located in the I.2 region of the aromatase gene (rs1062033) and a T/C SNP located in the first intron of the estrogen receptor (rs2234693) were typed using Taqman assays (Applied Biosystems), as previously reported [10, 11] .
Gene expression
Bone samples were obtained from the femoral neck during hip replacement procedures for hip fractures in 43 patients. In brief, small fragments of trabecular bone were extensively washed with PBS, snap-frozen in liquid nitrogen and stored at −70°C. Unthawed fragments were mashed and pulverized with a tissue homogenizer into Trizol (Invitrogen) to extract RNA. RNA integrity was checked by gel electrophoresis and the concentration measured by absorptiometry. Aliquots of RNA (about 1 μg) were reversetranscribed with the Superscript III kit (Invitrogen), using random hexamers as primers. In negative control reactions reverse transcriptase was omitted. After RT-PCR, aromatase gene expression was determined by real-time PCR in an ABI7300 apparatus (Applied Biosystems). The reactions were performed in triplicate in 96-well plates containing aliquots of the cDNA obtained by reverse transcription, 5 μl of universal PCR master mix, and primers and probe complementary to the I.2 exon sequence (Taqman Gene Expression Assays, Applied Biosystems).
The cycle threshold (Ct) was determined. This represents the cycle at which a significant increase in fluorescence is first detected and is inversely related to the amount of target cDNA in the starting material. In samples with nondetectable amplification of aromatase, the Ct was arbitrarily set at 44. The results were normalized to TBP (TATA box binding protein) expression analyzed in the same reaction plate. Control samples of reverse-transcribed reference human RNA (Stratagene, La Jolla, CA, USA) were also included. The relative RNA levels were calculated using the formula 2
ΔCt1ÀΔCt2 , where ΔCt1 is the difference between the control cDNA Ct and the sample cDNA Ct when the target gene (aromatase) is amplified, and ΔCt2 is the difference between control cDNA Ct and the sample cDNA Ct when the control gene (TBP) is amplified.
Statistical analysis
The Hardy-Weinberg equilibrium was tested with HWSIM software http://krunch.med.yale.edu/hwsim/hwsim.doc). The characteristics of the control and fracture groups were compared by means of the t test, the Mann-Whitney U test or the χ 2 test. Differences in genotype distribution were analyzed using the χ 2 test. The association between genotypes and fractures was studied using logistic regression analysis. The non-parametric Jonckheere-Terpstra test for ordered categories and the U test were used to analyze the differences in aromatase gene expression between participants with different genotypes. SPSS software was used (SPSS, Chicago, IL, USA).
Results
Association between genotypes and fractures
The main characteristics of the two groups are shown in Table 1 . As expected, women with fractures were slightly older and had more comorbid conditions than control women.
There was no evidence of departure from the HardyWeinberg equilibrium (p=0.31 and 0.27, for the aromatase and the estrogen receptor genes respectively). The distribution of genotypes in the control and fracture groups is shown in Table 2 . Genotype frequencies were similarly distributed in both groups. According to the results of previous studies, we combined aromatase and estrogen receptor genotypes into two groups (CC and CG +GG for the aromatase, and TT and TC+CC for the estrogen receptors) and performed a logistic regression analysis. It revealed a significant gene-gene interaction (p=0.007 in unadjusted models and 0.004 in age-adjusted models). In the group of women bearing TC/CC alleles of the estrogen receptor there was no association between aromatase and fractures. However, among women with TT alleles of the estrogen receptor, the CC aromatase genotype was significantly more common in women with fractures than in controls (39 vs. 23%, p=0.009). Thus, the unadjusted odds ratio was 2.1 (95% confidence interval 1.2-3.8) and the age-adjusted odds ratio was 2.4 (95% confidence interval 1.3-4.4, p=0.005). There was no evidence of an interaction of age with the association between aromatase genotype and hip fracture (p=0.41), and similar odds ratios were found in women under 80 years of age (2.6, 95% confidence interval 1.0-6.9) and in those aged over 80 (2.5, 95% confidence interval 1.1-5.6). Adjustment by other potential confounding factors (calcium intake, tobacco or alcohol consumption, comorbidities) did not significantly change the estimated odds ratio (not shown). In Table 3 we show the distribution of the women across the four groups defined by aromatase and estrogen receptor genotypes. The odds ratio for fractures in women with the CC aromatase genotype and the TT estrogen receptor genotype was 2.0 (95% CI 1.2-3.4), in comparison with women with any other genotype, and 1.9 (95% CI 1.1-3.2) in comparison with women with the CG/GG aromatase genotype and the TC/CC estrogen receptor genotype.
Aromatase gene expression
Aromatase transcripts containing the I.2 exon sequence were detected in bone samples from 37 out of 43 patients. Aromatase alleles were associated with gene expression. As shown in Fig. 1 , aromatase transcripts were significantly less abundant in samples taken from women with the CC genotype than in samples from women with other genotypes. No significant differences existed between the CG and GG genotypes.
Discussion
The association between estrogen receptor gene polymorphisms and osteoporosis has been extensively studied. The rs2234693 SNP analyzed here has been a subject of particular interest. In the literature it has been commonly referred to as the PvuII polymorphism, as many investigators characterized it by using the PvuII restriction enzyme [13] [14] [15] [16] . In this study we did not find significant differences in estrogen receptor allele or genotype distribution between hip fracture patients and controls. Similar negative results have been reported by other investigators [17] [18] [19] [20] .
To our knowledge this is the first published study about the relationship between aromatase gene polymorphisms and hip fractures. Our results suggest that this polymorphism of the aromatase gene, previously shown to be associated with BMD, is associated with hip fractures in women bearing a certain genotype of the estrogen receptor.
We did not find evidence of a significant association between either gene polymorphism and hip fractures when they were analyzed separately, but the association was revealed in the combined analysis. This is consistent with a small effect of each gene variant, which can only be demonstrated in the joint analysis, and represents an example of epistasis (gene-gene interaction) between two genes involved in estrogen metabolism. Specifically, those genes are related to estrogen synthesis and estrogen response respectively. Thus, such interaction seems plausible from a biological point of view. Furthermore, these findings fit the contention that these genes contribute to explain the genetic component of osteoporosis. In fact, we and others have demonstrated that several polymorphisms of the aromatase gene are associated with differences in BMD, estrogen circulating levels in postmenopausal women, and osteoporotic vertebral fractures [8-10, 12, 21-26] .
These polymorphisms are situated in non-coding regions. Therefore, their association with osteoporosis must be due to differences in gene expression, not to changes in protein sequences. In fact, it has been suggested that the rs2234693 SNP in intron 1 of the estrogen receptor might modulate gene transcription. The C allele, but not the T allele, contains a functional Myb binding site and transfection experiments with luciferase reporters showed a 4-fold higher transcription rate in cells incorporating constructs with the C allele, in comparison with those transfected with constructs bearing the T allele [27] . These results would suggest that cells with T alleles express fewer estrogen receptor molecules, which could render them more sensi- tive to a reduced supply of estrogen. Although merely speculative, this mechanism would be consistent with our findings showing that different genotypes of the estrogensynthesizing aromatase are associated with BMD in women with T alleles, but not in those with C alleles [11] .
On the other hand, we provide evidence that aromatase alleles are associated with differences in gene expression. Aromatase transcripts were less abundant in bone samples from women with CC genotypes than in women with CG or GG genotypes. These results fit with the association data, for the CC genotype was related to a higher risk of hip fractures. They also agree with our previous data showing a relationship between aromatase genotype and gene expression in the adipose tissue [21] . Therefore, we hypothesize that women with TT alleles of the estrogen receptor are more sensitive to small changes in estrogen availability, such as those determined by aromatase allelic variants. Thus, women with unfavorable variants of both genes are at increased risk of hip fractures. The molecular mechanism involved in the differences in aromatase RNA levels across different genotypes has not been elucidated, but it is likely to depend on differences in the ability to bind transcription factors, which in turn results in differential allelic expression [21] . Whatever the mechanism might be, women with C alleles appear to express less aromatase at the tissue level and are therefore likely to have less bioavailable estradiol after the menopause, which in the long term will have a deleterious influence on the bone mass and result in a higher risk of fractures. Only in homozygotes for the C allele, but not in the heterozygotes, did we observe statistically significant differences in aromatase gene expression and hip fracture risk. Therefore, our data fitted a recessive genetic model better.
This study has several limitations. Some of them are inherent to a case-control design and the difficulty in recruiting elderly control participants. As a consequence, there was some imbalance between fracture and controls regarding age and other characteristics. It may theoretically introduce some bias, but the association between gene variants and fracture risk did not change when those differences were taken into consideration in multivariate models or age-stratified analysis. Moreover, since the control participants were somewhat younger than the fracture patients, it might be expected that such potential bias would tend to change the results toward the null hypothesis (i.e., some control women might perhaps suffer fractures in the future), thus making our data conservative estimates of the association between genotypes and fractures. Nevertheless, the results should ideally be confirmed in longitudinal studies to strengthen the conclusions. Also, due to the lack of complete anthropometric data in fracture patients, we were unable to adjust the results for certain factors that may have an important influence on bone homeostasis, such as body weight. We have previously shown an association between aromatase and estrogen receptor gene polymorphisms and BMD [26, 28] . Since we did not have BMD data in hip fracture patients, we were not able to establish to what extent the association between the aromatase genotype and hip fractures was dependent on differences in BMD.
It has been estimated that genetic factors explain about 50-80% of BMD variance and many studies have addressed the association between candidate genes and BMD. Although more difficult to demonstrate because of the occurrence of multiple potential confounding factors in the elderly population, hip fractures also have a genetic component, as revealed by the increased risk in daughters of patients who have suffered fractures [29, 30] . In a recent study, Michaelsson et al. estimated that the global ageadjusted heritability of hip fractures was 48%, but this decreased with advancing age [31] . In this study we show that some allelic variants of the aromatase gene interact with the estrogen receptor gene to explain, in part, that genetic influence on hip fracture risk.
